Your browser is no longer supported. Please, upgrade your browser.
Geron Corporation
Index- P/E- EPS (ttm)-0.33 Insider Own0.17% Shs Outstand328.94M Perf Week-9.80%
Market Cap424.13M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float321.40M Perf Month-12.10%
Income-107.90M PEG- EPS next Q-0.10 Inst Own41.90% Short Float5.84% Perf Quarter-5.48%
Sales0.40M P/S1060.32 EPS this Y22.70% Inst Trans1.35% Short Ratio10.55 Perf Half Y-1.43%
Book/sh0.46 P/B3.00 EPS next Y-16.70% ROA-42.70% Target Price4.20 Perf Year-25.00%
Cash/sh0.57 P/C2.41 EPS next 5Y5.00% ROE-58.30% 52W Range1.20 - 2.36 Perf YTD-13.21%
Dividend- P/FCF- EPS past 5Y- ROI-32.70% 52W High-41.40% Beta1.06
Dividend %- Quick Ratio4.70 Sales past 5Y-63.00% Gross Margin- 52W Low15.00% ATR0.09
Employees53 Current Ratio4.70 Sales Q/Q0.00% Oper. Margin- RSI (14)39.71 Volatility6.11% 5.76%
OptionableYes Debt/Eq0.23 EPS Q/Q-31.70% Profit Margin- Rel Volume1.26 Prev Close1.48
ShortableYes LT Debt/Eq0.23 EarningsAug 16 AMC Payout- Avg Volume1.78M Price1.38
Recom1.80 SMA20-11.17% SMA50-6.31% SMA200-6.31% Volume2,250,268 Change-6.76%
Nov-02-21Initiated Robert W. Baird Outperform $4
Feb-18-21Resumed B. Riley Securities Buy $4
Aug-03-20Initiated Stifel Buy $3
Nov-19-19Resumed B. Riley FBR Buy $4
Sep-03-19Initiated H.C. Wainwright Buy $4
Aug-15-19Initiated Cantor Fitzgerald Overweight $4
Apr-09-19Upgrade Needham Hold → Buy $3
Jan-31-19Upgrade B. Riley FBR Neutral → Buy $1.50 → $3.25
Oct-02-18Downgrade B. Riley FBR Buy → Neutral $5.75 → $1.50
Jul-05-18Initiated B. Riley FBR, Inc. Buy $5.75
Sep-13-16Reiterated FBR Capital Outperform $6 → $5
Sep-13-16Reiterated FBR & Co. Outperform $6 → $5
Dec-07-15Reiterated Piper Jaffray Overweight $5 → $10
Apr-21-15Initiated Oppenheimer Outperform $5.50
Jun-12-14Upgrade MLV & Co Hold → Buy $2 → $4.25
Mar-12-14Downgrade MLV & Co Buy → Hold $9 → $2
Dec-10-13Upgrade Needham Hold → Buy $10
Dec-10-13Reiterated MLV & Co Buy $8 → $9
Nov-08-13Reiterated MLV & Co Buy $6.50 → $8
Oct-16-13Initiated MLV & Co Buy $6.50
Nov-18-21 04:30PM  
Nov-12-21 07:30AM  
Nov-09-21 09:05PM  
Nov-04-21 09:12AM  
Oct-31-21 10:44AM  
Oct-28-21 03:06PM  
Oct-25-21 04:30PM  
Oct-21-21 04:30PM  
Oct-18-21 07:30AM  
Oct-15-21 04:05PM  
Oct-11-21 04:30PM  
Sep-16-21 04:30PM  
Sep-01-21 04:30PM  
Aug-28-21 08:01AM  
Aug-19-21 04:30PM  
Aug-17-21 08:28AM  
Aug-16-21 05:25PM  
Aug-05-21 04:30PM  
Aug-02-21 06:09AM  
Jul-29-21 03:05PM  
Jul-22-21 04:45PM  
Jun-21-21 12:15PM  
Jun-18-21 11:40AM  
Jun-17-21 04:30PM  
Jun-14-21 04:30PM  
May-12-21 10:56AM  
May-11-21 02:01AM  
May-10-21 05:55PM  
May-04-21 10:37AM  
May-03-21 04:30PM  
Apr-27-21 04:36AM  
Apr-22-21 04:30PM  
Apr-20-21 04:01PM  
Apr-19-21 09:30AM  
Apr-18-21 08:00AM  
Apr-14-21 09:40AM  
Apr-13-21 07:30AM  
Mar-18-21 04:45PM  
Mar-12-21 12:06PM  
Mar-11-21 04:10PM  
Mar-10-21 10:08AM  
Mar-04-21 12:30PM  
Mar-01-21 04:45PM  
Feb-18-21 04:45PM  
Feb-07-21 03:54AM  
Jan-21-21 04:45PM  
Jan-14-21 04:45PM  
Dec-17-20 01:25PM  
Dec-11-20 08:30AM  
Dec-10-20 08:30AM  
Dec-07-20 06:45PM  
Nov-19-20 04:30PM  
Nov-10-20 04:30PM  
Nov-08-20 07:51AM  
Nov-06-20 10:31AM  
Nov-05-20 07:20PM  
Nov-04-20 04:27PM  
Nov-02-20 11:58AM  
Oct-29-20 04:30PM  
Oct-28-20 04:35PM  
Oct-23-20 09:03AM  
Oct-01-20 04:30PM  
Sep-21-20 08:53AM  
Sep-17-20 04:30PM  
Sep-09-20 09:00AM  
Aug-24-20 10:52AM  
Aug-20-20 04:30PM  
Aug-06-20 04:05PM  
Aug-04-20 04:45PM  
Jul-30-20 04:30PM  
Jul-27-20 08:28AM  
Jul-23-20 11:30AM  
Jul-16-20 08:30AM  
Jul-01-20 08:30AM  
Jun-30-20 08:01AM  
Jun-25-20 10:36AM  
Jun-24-20 12:35PM  
Jun-22-20 11:28AM  
Jun-19-20 08:50AM  
Jun-12-20 08:30AM  
Jun-11-20 09:04AM  
Jun-10-20 09:30AM  
Jun-09-20 09:44AM  
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.